LGD 3437

Drug Profile

LGD 3437

Alternative Names: LGD-3437

Latest Information Update: 19 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ligand Pharmaceuticals
  • Class
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Hypersomnia

Highest Development Phases

  • Preclinical Hypersomnia

Most Recent Events

  • 01 Sep 2015 LGD 3437 is available for licensing as of 01 Sep 2015. http://www.ligand.com/
  • 01 Sep 2015 Preclinical trials in Hypersomnia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top